Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland.
CPE score
HIV
aging
cognitive disorders
neurocognitive impairment
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
15
03
2019
accepted:
03
07
2019
entrez:
16
7
2019
pubmed:
16
7
2019
medline:
16
7
2019
Statut:
epublish
Résumé
Neurocognitive impairment (NCI) in people with human immunodeficiency virus (PWH) remains a concern despite potent antiretroviral therapy (ART). Higher central nervous system (CNS) penetration effectiveness (CPE) scores have been associated with better CNS human immunodeficiency virus (HIV) replication control, but the association between CPE and NCI remains controversial. The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study is a subgroup of the Swiss HIV Cohort Study (SHCS) that invited patients aged ≥45 years enrolled in the SHCS and followed-up at NAMACO-affiliated centers in Switzerland to participate between May 2013 and November 2016. In total, 981 patients were enrolled, all of whom underwent standardized neurocognitive assessment. Neurocognitive impairment, if present, was characterized using Frascati criteria. The CPE scores of NAMACO study participants with undetectable plasma HIV-ribonucleic acid at enrollment (909 patients) were analyzed. Cross-sectional CPE scores (at neurocognitive assessment) were examined as potential predictors of NCI in multivariate logistic regression models. The analysis was then repeated taking CPE as a cumulative score (summarizing CPE scores from ART initiation to the time of neurocognitive assessment). Most patients were male (80%) and Caucasian (92%). Neurocognitive impairment was present in 40%: 27% with HIV-associated NCI (mostly asymptomatic neurocognitive impairment), and 13% with NCI related to other factors. None of the CPE scores, neither cross-sectional nor cumulative, was statistically significantly associated with NCI. In this large cohort of aviremic PWH, we observed no association between NCI, whether HIV-associated or related to other factors, and CPE score, whether cross-sectional or cumulative.
Sections du résumé
BACKGROUND
BACKGROUND
Neurocognitive impairment (NCI) in people with human immunodeficiency virus (PWH) remains a concern despite potent antiretroviral therapy (ART). Higher central nervous system (CNS) penetration effectiveness (CPE) scores have been associated with better CNS human immunodeficiency virus (HIV) replication control, but the association between CPE and NCI remains controversial.
METHODS
METHODS
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study is a subgroup of the Swiss HIV Cohort Study (SHCS) that invited patients aged ≥45 years enrolled in the SHCS and followed-up at NAMACO-affiliated centers in Switzerland to participate between May 2013 and November 2016. In total, 981 patients were enrolled, all of whom underwent standardized neurocognitive assessment. Neurocognitive impairment, if present, was characterized using Frascati criteria. The CPE scores of NAMACO study participants with undetectable plasma HIV-ribonucleic acid at enrollment (909 patients) were analyzed. Cross-sectional CPE scores (at neurocognitive assessment) were examined as potential predictors of NCI in multivariate logistic regression models. The analysis was then repeated taking CPE as a cumulative score (summarizing CPE scores from ART initiation to the time of neurocognitive assessment).
RESULTS
RESULTS
Most patients were male (80%) and Caucasian (92%). Neurocognitive impairment was present in 40%: 27% with HIV-associated NCI (mostly asymptomatic neurocognitive impairment), and 13% with NCI related to other factors. None of the CPE scores, neither cross-sectional nor cumulative, was statistically significantly associated with NCI.
CONCLUSIONS
CONCLUSIONS
In this large cohort of aviremic PWH, we observed no association between NCI, whether HIV-associated or related to other factors, and CPE score, whether cross-sectional or cumulative.
Identifiants
pubmed: 31304188
doi: 10.1093/ofid/ofz277
pii: ofz277
pmc: PMC6612860
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz277Références
AIDS. 2006 Aug 1;20(12):1591-5
pubmed: 16868439
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Arch Neurol. 2008 Jan;65(1):65-70
pubmed: 18195140
AIDS. 2009 Jul 17;23(11):1359-66
pubmed: 19424052
Neuropsychol Rev. 2009 Jun;19(2):186-203
pubmed: 19472057
J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63
pubmed: 19731418
Int J Epidemiol. 2010 Oct;39(5):1179-89
pubmed: 19948780
AIDS. 2010 Jun 1;24(9):1243-50
pubmed: 19996937
Clin Infect Dis. 2010 Mar 1;50(5):773-8
pubmed: 20100092
Top HIV Med. 2010 Apr-May;18(2):45-55
pubmed: 20516524
Neurology. 2010 Sep 7;75(10):864-73
pubmed: 20702792
Neurology. 2010 Sep 28;75(13):1150-8
pubmed: 20739646
J Infect Dis. 2010 Dec 15;202(12):1819-25
pubmed: 21050119
AIDS. 2011 Jan 28;25(3):357-65
pubmed: 21124201
Neurology. 2010 Dec 7;75(23):2087-96
pubmed: 21135382
J Neurovirol. 2011 Feb;17(1):3-16
pubmed: 21174240
Top Antivir Med. 2011 Nov;19(4):137-42
pubmed: 22156215
AIDS. 2012 Sep 10;26(14):1765-74
pubmed: 22614889
J Neurovirol. 2012 Oct;18(5):388-99
pubmed: 22811264
Antivir Ther. 2012;17(7):1233-42
pubmed: 23018140
J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35
pubmed: 23018371
Clin Infect Dis. 2013 Apr;56(7):1004-17
pubmed: 23175555
J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):180-9
pubmed: 23187939
Antivir Ther. 2013;18(2):153-60
pubmed: 23486721
Antivir Ther. 2013;18(2):149-51
pubmed: 23486740
AIDS. 2014 Feb 20;28(4):493-501
pubmed: 24472743
Neurology. 2014 Jul 8;83(2):134-41
pubmed: 24907236
Clin Infect Dis. 2014 Oct;59(7):1032-7
pubmed: 24944232
Lancet Neurol. 2014 Nov;13(11):1139-1151
pubmed: 25316020
HIV Med. 2015 Apr;16 Suppl 1:97-108
pubmed: 25711328
J Neuroimmune Pharmacol. 2015 Sep;10(3):487-92
pubmed: 25900078
J Neurovirol. 2016 Jun;22(3):349-57
pubmed: 26572786
J Infect Dis. 2017 Jan 1;215(1):105-113
pubmed: 27789723
J Neurovirol. 2017 Apr;23(2):216-225
pubmed: 27815816
Open Forum Infect Dis. 2017 Apr 06;4(2):ofx070
pubmed: 28584853
J Infect Dis. 1997 Apr;175(4):963-6
pubmed: 9086160